Clinical Trial Update: A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) [Phase 1, Phase 2]

View source ↗

Summary

ELU001, studied in Phase 1/2 in FRα-overexpressing solid tumors, has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Ovarian Cancer

Drugs mentioned

• ELU001

Snippet

Sponsor: Elucida Oncology | Conditions: Ovarian Cancer, Ovarian Neoplasms | Phase 1, Phase 2 | Status: TERMINATED